Of 204 patients with MLH1‐ and MLH1/PMS2‐deficient tumours, 199 (97·5 per cent) underwent reflex BRAF mutational testing to screen for Lynch syndrome, of whom 58 (29·1 per cent) were BRAF wild‐type. This evidence concerns the gene MLH1 and neoplasm.